The Lupus Research Alliance and clinical affiliate Lupus Therapeutics are proud to be selected as inaugural collaborators of the new life sciences investment firm, Vie Ventures.
Vie Ventures is focused on bridging venture capital and disease philanthropy. The organization is concentrating on advancing late-stage, breakthrough therapies for autoimmune diseases and other immune system disorders where there is great patient need.
As a strategic collaborator to Vie Ventures, representatives from the Lupus Research Alliance and Lupus Therapeutics will help integrate the lupus patient perspective, provide updates on the lupus research landscape, inform investment strategies, and, ultimately, advance next-generation therapies for people with lupus.
The additional collaborators in Vie Ventures’ inaugural coalition are the Crohn’s and Colitis Foundation, National Multiple Sclerosis Society, Scleroderma Research Foundation, and Sjögren’s Foundation.
“The critical need for safe and effective treatment options to help people with autoimmune diseases requires collaboration throughout the drug development process,” Albert T. Roy, President and CEO of the Lupus Research Alliance, said. “The Lupus Research Alliance and Lupus Therapeutics are proud to partner with Vie Ventures, contributing our expertise in lupus research to accelerate late-stage clinical advancements.”
